To assess the real-world use and effectiveness of belimumab in routine practice for the treatment of adults with active lupus nephritis. Aims to provide the first long-term assessment of renal function preservation in patients treated with belimumab.
Retrospective and prospective data collection from patients with LN who take belimumab.
Diagnosis of lupus nephritis (LN) and taking or planning to start belimumab. Male or female aged 18 or over at initiation of belimumab, Received belimumab for the treatment of active LN prescribed as per local label in combination with standard immunosuppressive therapy/ies at initiation of belimumab,Initiation of belimumab 6-24 months prior to study enrollment, Accessibility of a medical records starting at belimumab initiation (including accessibility of medical records for the prior 12 months and confirmatory biopsy within the prior 24 months from belimumab initiation), Biopsy-confirmed diagnosis of active LN in the two-years prior to the initiation of belimumab o Class III (focal LN) with or without Class V (membranous LN), o Class IV (diffuse LN) with or without Class V, o Class V.
Principal Investigator